Aelius Biotech

Aelius Biotech develops laboratory gut models to test drugs and foodstuffs without animal trials.

Newcastle upon Tyne, UK—Founded 2018

£2.0MTotal raised

Aelius Biotech provides laboratory testing services using an innovative gut model to simulate human digestion for the food and pharmaceutical industries. The company was founded by university researchers to offer alternatives to animal testing.

Founders

Peter Chater

CEO

Matt Wilcox

Jeff Pearson

Investors

Seed8 April 2025
£750K
Mercia Ventures
North East Venture FundFollow-on
23 November 2023
£1.3M
North East Venture FundLead

Funding history

Seed8 April 2025

£750K

Aelius Biotech secures £750k from Mercia Ventures and the North East Venture Fund to fuel international expansion.

The biotechnology firm raised fresh capital to accelerate growth in American and European markets and complete new laboratory facilities.

23 November 2023

£1.3M

Aelius Biotech raises £1.3m from the North East Venture Fund to expand operations and research.

The funding round was managed by Mercia Ventures and will support lab relocation and team expansion.